Biosimilar Solutions Initiates Registrational Clinical Trial for Biosimilar Version Neulasta
April 13, 2022 13:31 ET
|
OcyonBio (ocyonbio.com)
AGUADILLA, Puerto Rico, April 13, 2022 (GLOBE NEWSWIRE) -- OcyonBio, LLC's client Biosimilar Solutions, Inc., announces it has started its registrational clinical trials for the biosimilar version...
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
March 29, 2022 09:15 ET
|
Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
OcyonBio Client Biosimilar Solutions, Inc. Initiates Registrational Clinical Trial for Its First Biosimilar Product
March 23, 2022 12:00 ET
|
OcyonBio (ocyonbio.com)
AGUADILLA, Puerto Rico, March 23, 2022 (GLOBE NEWSWIRE) -- Biosimilar Solutions, Inc. announces it has started its registrational clinical trials for BSC1020®, a recombinant filgrastim product...
OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico
March 14, 2022 11:46 ET
|
OcyonBio (ocyonbio.com)
AGUADILLA, Puerto Rico, March 14, 2022 (GLOBE NEWSWIRE) -- OcyonBio announces manufacturing and operations agreement to develop biosimilar drug product facilities for Biosimilar Solutions, Inc....
Biosimilars Market to Reach USD 103.94 Billion by 2028 - Low Priced Biosimilars to Boost the Market Demand – Vantage Market Research
February 14, 2022 03:39 ET
|
Vantage Market Research
WASHINGTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The Global Biosimilars Market size is expected to reach USD 103.94 Billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 25.6% during the...
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
January 10, 2022 07:30 ET
|
Coherus BioSciences, Inc.
• Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types • Combinations of PD-1 + TIGIT inhibitors have potential to expand...
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 20, 2021 07:59 ET
|
Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
Biotech Ingredients Market Size to Reach $75.3 Billion by 2028 | CAGR: 4.8%: AMR
June 14, 2021 10:36 ET
|
Allied Market Research
Portland, OR, June 14, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global biotech ingredients market was pegged at $51.3 billion in 2020 and is...
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
May 17, 2021 10:44 ET
|
Novartis Pharma AG
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by...
New ACR White Paper Highlights Health Care Challenges Affecting the Rheumatic Disease Community
May 12, 2021 12:28 ET
|
American College of Rheumatology
Atlanta, May 12, 2021 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) today announced the launch of a new white paper, “Rheumatic Diseases in America: Confronting the Challenge,”...